Deciding Management for Early HER2-Positive Breast Cancer

home / case-based-roundtable-series / deciding-management-for-early-her2-positive-breast-cancer

This roundtable series reviews the selection of regimens for patients with HER2-positive breast cancer as discussed by participants at virtual live events.

Subcutaneous Regimen Shows Noninferiority to Intravenous in HER2+ Breast Cancer

Subcutaneous Regimen Shows Noninferiority to Intravenous in HER2+ Breast Cancer

William J. Gradishar, MD
December 24th 2021

William J. Gradishar, MD, discusses the design and results of a study of intravenous versus subcutaneous pertuzumab and trastuzumab in patients with HER2-positive breast cancer.

Patients Prefer Subcutaneous Regimen for HER2-Positive Breast Cancer

Patients Prefer Subcutaneous Regimen for HER2-Positive Breast Cancer

Andrew Seidman, MD
January 6th 2022

Andrew Seidman, MD, discusses the PHranceSCa trial of patient preference for intravenous versus subcutaneous trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer.

Subcutaneous Regimen Shows Non-Inferiority for HER2+ Breast Cancer

Subcutaneous Regimen Shows Non-Inferiority for HER2+ Breast Cancer

Andrew D. Seidman, MD
February 16th 2022

Andrew Seidman, MD, discusses the FeDeriCa trial of intravenous versus subcutaneous trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer.

Pharmacokinetics of Subcutaneous HER2 Therapy Noninferior in BC

Pharmacokinetics of Subcutaneous HER2 Therapy Noninferior in BC

Rebecca A. Shatsky, MD
February 29th 2024

Rebecca A. Shatsky, MD, discusses the outcomes of the phase 3 FeDeriCa study of subcutaneous trastuzumab and pertuzumab in patients with HER2-positive breast cancer.

Advantages of SC HER2 Therapy Over IV Administration in Breast Cancer

Advantages of SC HER2 Therapy Over IV Administration in Breast Cancer

Rebecca A. Shatsky, MD
March 7th 2024

Rebecca A. Shatsky, MD, discusses the advantages of giving patients with HER2-positive breast cancer a subcutaneous injection of targeted therapy compared with the intravenous formulation of trastuzumab and pertuzumab.